Literature DB >> 11261619

Laparoscopic adrenalectomy is superior to an open approach to treat primary hyperaldosteronism.

J L Duncan1, G M Fuhrman, J S Bolton, J D Bowen, W S Richardson.   

Abstract

We reviewed our institutional experience with primary hyperaldosteronism to compare clinical outcomes after laparoscopic versus open adrenalectomy. All patients surgically treated for primary hyperaldosteronism from 1988 through 1999 are included in this study. Patients were assigned to either the LA (laparoscopic) or OA (open) group depending on the initial surgical approach selected for treatment. Records were reviewed to determine demographics, operative results, and complications. Twenty-four patients were surgically treated for primary hyperaldosteronism. There were no significant differences between groups with respect to age, weight, number of preoperative antihypertensive medications, or preoperative potassium level. The results of adrenalectomy with respect to number of postoperative antihypertensive medications or serum potassium level were also similar. Operative times were not significantly different (191 +/- 53 minutes for OA and 205 +/- 88 minutes for LA) between groups, but four LA patients were converted to OA. Estimated blood loss was 401 +/- 513 cm3 for OA and 127 +/- 131 cm3 for LA (P = 0.07). Hospital length of stay was 6.7 +/- 3.7 days for OA and 3.3 +/- 2.7 days for LA (P = 0.02). Complications were nine for OA and three for LA (P = 0.001 by Pearson's Chi square). LA is similar to OA in the treatment of primary hyperaldosteronism. The significantly fewer complications and shorter length of hospital stay associated with LA makes the laparoscopic approach the preferred method for treating primary hyperaldosteronism.

Entities:  

Mesh:

Year:  2000        PMID: 11261619

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  13 in total

1.  [A 58-year-old hypertensive patient with primary hyperaldosteronism and renal artery stenosis].

Authors:  Michael Nguyen Quang; Bernd Krüger; Christopher D Krüger; Andreas Walberer; Bernhard Schenck; Klaus Kisters; Martin Wenning; Bernhard K Krämer
Journal:  Med Klin (Munich)       Date:  2010-04

2.  SAGES guidelines for minimally invasive treatment of adrenal pathology.

Authors:  Dimitrios Stefanidis; Melanie Goldfarb; Kent W Kercher; William W Hope; William Richardson; Robert D Fanelli
Journal:  Surg Endosc       Date:  2013-09-10       Impact factor: 4.584

3.  Issue editor.

Authors:  A Burshell
Journal:  Ochsner J       Date:  2001-07

4.  Minimally invasive abdominal surgery.

Authors:  W S Richardson; K M Carter; G M Fuhrman; J S Bolton; J C Bowen
Journal:  Ochsner J       Date:  2000-07

Review 5.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

Review 6.  Primary Aldosteronism: Cardiovascular Outcomes Pre- and Post-treatment.

Authors:  Gregory L Hundemer
Journal:  Curr Cardiol Rep       Date:  2019-07-27       Impact factor: 2.931

7.  Changing pattern of the intraoperative blood pressure during endoscopic adrenalectomy in patients with Conn's syndrome.

Authors:  I Gockel; A Heintz; R Kentner; C Werner; C Wetner; Th Junginger
Journal:  Surg Endosc       Date:  2005-09-29       Impact factor: 4.584

8.  Transition from open to laparoscopic adrenalectomy: the need for advanced training.

Authors:  D L Maccabee; A Jones; J Domreis; C W Deveney; B C Sheppard
Journal:  Surg Endosc       Date:  2003-07-21       Impact factor: 4.584

9.  Bilateral adrenalectomy for ectopic Cushing's syndrome-discussions on technique and indication.

Authors:  Per Hellman; Fredrik Linder; Joakim Hennings; Ola Hessman; Barbro Eriksson; Håkan Orlefors; Göran Akerström
Journal:  World J Surg       Date:  2006-05       Impact factor: 3.352

Review 10.  Surgical approach to patients with primary aldosteronism.

Authors:  Catherine McManus; Jennifer H Kuo
Journal:  Gland Surg       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.